ALKS:NSD-Alkermes plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.00

Change

0.00 (0.00)%

Market Cap

USD 4.72B

Volume

1.85M

Avg Analyst Target

USD 29.86 (-0.48%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alkermes plc (ALKS) Stock Analysis:
Based on the Alkermes plc stock forecasts from 6 analysts, the average analyst target price for Alkermes plc is USD 29.86 over the next 12 months. Alkermes plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alkermes plc is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Alkermes plc’s stock price was USD 30.00. Alkermes plc’s stock price has changed by +11.61% over the past week, +2.53% over the past month and +35.20% over the last year.

About

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intra ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD19.45B 58.02 5.06
ARGX argenx SE

N/A

USD17.61B N/A N/A

ETFs Containing ALKS

Symbol Name Weight Mer Price(Change) Market Cap
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

N/A

USD0.11B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.98% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.98% 97% A+ 97% A+
Trailing 12 Months  
Capital Gain 35.20% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.20% 96% A 95% A
Trailing 5 Years  
Capital Gain -48.56% 54% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.56% 54% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -8.95% 35% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.95% 35% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 38.13% 73% C 40% F
Risk Adjusted Return -23.47% 32% F 26% F
Market Capitalization 4.72B 96% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.09 21% F 20% F
Price / Cash Flow Ratio 46.39 2% F 6% F
EV/EBITDA 193.16 2% F 4% F
Management Effectiveness  
Return on Equity -5.80% 90% A- 44% F
Return on Invested Capital -2.77% 88% B+ 43% F
Return on Assets -1.28% 92% A- 43% F
Debt to Equity Ratio 26.32% 46% F 55% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.46 62% D- 46% F
Short Percent 5.11% 47% F 33% F
Beta 0.90 73% C 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector